GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

muvalaplin   Click here for help

GtoPdb Ligand ID: 12939

Synonyms: LY-3473329 | LY3473329
PDB Ligand
Compound class: Synthetic organic
Comment: Muvalaplin (LY3473329) is an orally bioavailable small molecule that disrupts the binding of apolipoprotein(a) to apolipoprotein B100, thus blocking the formation of lipoprotein(a) [1,4]. It was designed to treat atherosclerotic disease. Muvalaplin does not bind to plasminogen.

muvalaplin is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 6
Rotatable bonds 18
Topological polar surface area 151.23
Molecular weight 710.9
XLogP 1.58
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=CC(=CC(=C1)C[C@@H]([C@H]2CCNC2)C(=O)O)CN(CC3=CC(=CC=C3)C[C@@H]([C@H]4CCNC4)C(=O)O)CC5=CC(=CC=C5)C[C@@H]([C@H]6CCNC6)C(=O)O
Isomeric SMILES C1CNC[C@H]1[C@H](CC2=CC(=CC=C2)CN(CC3=CC=CC(=C3)C[C@@H]([C@H]4CCNC4)C(=O)O)CC5=CC=CC(=C5)C[C@@H]([C@H]6CCNC6)C(=O)O)C(=O)O
InChI InChI=1S/C42H54N4O6/c47-40(48)37(34-10-13-43-22-34)19-28-4-1-7-31(16-28)25-46(26-32-8-2-5-29(17-32)20-38(41(49)50)35-11-14-44-23-35)27-33-9-3-6-30(18-33)21-39(42(51)52)36-12-15-45-24-36/h1-9,16-18,34-39,43-45H,10-15,19-27H2,(H,47,48)(H,49,50)(H,51,52)/t34-,35-,36-,37-,38-,39-/m0/s1
InChI Key BRLGERLDHZRETI-BGBFCPIGSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Muvalaplin was advanced to clinical evaluation as a treatment for atherosclerotic cardiovascular disease (ASCVD) [2-3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04472676 A Study of LY3473329 in Healthy Participants Phase 1 Interventional Eli Lilly and Company 4
NCT05563246 A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events Phase 2 Interventional Eli Lilly and Company